spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Envirotainer Significantly Expands Global CryoSure® Network With New Singapore Station

Envirotainer

Revolutionary -70°C cryogenic shipping now available across Asia and the Pacific


Stockholm, November 24, 2022: Envirotainer, the global market leader in secure cold chain solutions for shipment of pharmaceuticals, has opened a new CryoSure® station in Singapore. This significantly expands global availability of the ultra-cold solution for the transportation of medicines at -70°C.



The station sits near one of the largest airports in the world for international cargo traffic and a major hub for Asia and Pacific (APAC). This puts -70°C cryogenic shipping within reach of the fastest growing region in the pharmaceutical logistics market[i].

The new site complements Envirotainer’s existing presence in Singapore, ensures high global service levels and allows express orders throughout APAC.

CryoSure® is suitable for many ultra-cold chain uses such as cell and gene therapies, one of the fastest growing markets in the life sciences sector[ii]. Designed with extreme demands in mind, the solution comprises a range of dewars with unmatched performance and superior duration of up to three weeks without the need for refilling dry ice. They’re heat resistant with unparalleled ease-of-use, which further mitigates risk. It’s the most reliable choice for cryogenic -70°C shipments.

With this new addition to Envirotainer’s broad global network, customers will benefit from more efficient logistics. It not only improves the offering for customers in terms of speed and availability, but also sustainability.

CryoSure® is the most sustainable solution of its type on the market. The reusable dewars are noticeably less bulky than others and have two to three times better weight to volume efficiency compared to existing dry-ice boxes and liquid nitrogen (LN2) solutions. This translates into both significantly reduced transportation costs, as well as significantly lower carbon emissions.

Moving products at below -70°C is very challenging. Long journeys, combined with the risk of delays, human error and challenges with the supply and handling of dry ice can put shipments at risk. There is no room for failure when life-saving products need delivery.

With CryoSure® now available on a global scale, it will be possible to ensure vital treatments can be where and when needed quickly in most of Europe, North America and Asia. Expansion of the network will continue.

Fredrik Linnér, Chief Business Development said, “We’ve led the way in temperature-controlled shipments for decades and the expansion of our global CryoSure® network is another first. The solution fills a substantial gap in the cryogenic -70°C shipment market and its availability in the APAC region illustrates our ability and reach in a fast-growing and vitally important market.”


phone +46 18 34 73 00
email info@envirotainer.com
web www.envirotainer.com
email Head office R&D Manufacturing, Envirotainer AB, Lagga Marma, SE-741 93 Knivsta, Sweden
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Nova Biomedical Launches BioProfile® FAST CDV for High Throughput, Fully Automated Cell Density and Cell Viability Analysis

January 3, 2022 – Waltham, MA – Nova Biomedical is pleased to announce the launch of BioProfile FAST CDV™, a high-throughput, fully automated viable cell density and viability analyzer capable of producing results in under 70 seconds with just 100uL of sample volume. In addition, it performs all sample dilutions internally, enabling cell culture samples up to 140e6 c/mL to be analyzed without any external sample dilution. Cell culture samples can be analyzed via the external 36-position load-and-go tray or via an innovative 96-well plate option.
More info >>


White Papers

Case Study: Getting the Client’s Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmed’s performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement